<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03111966</url>
  </required_header>
  <id_info>
    <org_study_id>0001</org_study_id>
    <nct_id>NCT03111966</nct_id>
  </id_info>
  <brief_title>Effectiveness, Safety and Clinical Outcomes of Elbasvir/Grazoprevir: Results From a Spanish Real World Cohort</brief_title>
  <official_title>Effectiveness, Safety and Clinical Outcomes of Elbasvir/Grazoprevir: Results From a Spanish Real World Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hepa C</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hepa C</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre, descriptive, observational and ambispective study carried out in
      patients who are treated with Elbasvir/Grazoprevir in hospitals that included their data in
      Hepa-C Registry (directed by the Spanish Association for the Study of the Liver and the
      Networked Biomedical Research Centre for Hepatic and Digestive Diseases).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2017</start_date>
  <completion_date type="Anticipated">November 30, 2017</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>8 Months</target_duration>
  <primary_outcome>
    <measure>sustained virological response 12 weeks post-treatment (SVR12)</measure>
    <time_frame>12 weeks after the last dose of study drug</time_frame>
    <description>Percentage of participants who achieve sustained virological response 12 weeks post-treatment (SVR12)
• Measure: Hepatitis C virus ribonucleic acid (HCV-RNA) levels less than the lower limit of quantification.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>virologic failure</measure>
    <time_frame>Up to 8 weeks while on treatment</time_frame>
    <description>Percentage of patients with virologic failure during treatment
• Measure: Percentage of patients with confirmed &gt;=1 log10 IU/mL increase from nadir in HCV RNA at any time point during treatment or previous unquantifiable HCV up to 12 weeks after last dose of drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVR 12 and patients with mild fibrosis</measure>
    <time_frame>Up to 12 weeks after last dose of study drug</time_frame>
    <description>Percentage of patients with mild fibrosis who achieve sustained virological response 12 (SVR12) weeks post-treatment
• Measure: percentage of patients with a baseline transient elastography &lt; 6 kPa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>low baseline viral load and SVR12</measure>
    <time_frame>Baseline and 12 weeks after the last dose of drug</time_frame>
    <description>Percentage of participants with low baseline viral load who achieve sustained
• Measure: HCV RNA levels less than the lower limit of quantification.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Spanish cohort with HCV treated with DAA</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Spanish cohort with HCV treated in real practice with Elbasvir/Grazoprevir</intervention_name>
    <description>Spanish cohort with HCV treated in real practice with Elbasvir/Grazoprevir</description>
    <arm_group_label>Spanish cohort with HCV treated with DAA</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with HCV who are treated in real practice with Elbasvir/Grazoprevir
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18 years to 100 years (adult).

          -  Sexes: all

          -  Healthy volunteers: no

          -  Chronic hepatitis C (anti-HCV antibodies and detectable HCV-RNA).

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marta Hernández Conde</last_name>
    <email>marta.hernandez.conde@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HepaC</name>
      <address>
        <city>Madrid</city>
        <zip>28020</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Hernández Conde</last_name>
      <phone>0034679611532</phone>
      <email>marta.hernandez.conde@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2017</study_first_submitted>
  <study_first_submitted_qc>April 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <last_update_submitted>April 11, 2017</last_update_submitted>
  <last_update_submitted_qc>April 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

